CSIMarket
 


Respirerx Pharmaceuticals Inc   (RSPI)
Other Ticker:  
 
 

RSPI's Operating Income Growth by Quarter and Year

Respirerx Pharmaceuticals Inc 's Operating Income results by quarter and year




RSPI Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -0.22 -0.51 -0.87
III Quarter September - -0.39 -0.58 -1.31
II Quarter June -0.47 -0.35 -0.66 -0.62
I Quarter March -0.39 -0.62 -0.80 -0.52
FY   -0.86 -1.58 -2.55 -3.32



RSPI Operating Income second quarter 2023 Y/Y Growth Comment
Respirerx Pharmaceuticals Inc in the second quarter 2023 recorded Operating Loss of $ -0.47 millions.

According to the results reported in the second quarter 2023, Respirerx Pharmaceuticals Inc achieved the best Operating Income growth in Major Pharmaceutical Preparations industry. While Respirerx Pharmaceuticals Inc ' s Operating Income no change of % ranks overall at the positon no. in the second quarter 2023.

Explain Operating Income growth


RSPI Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Respirerx Pharmaceuticals Inc 's second quarter 2023 Operating Income $ -0.47 millions RSPI's Income Statement
Respirerx Pharmaceuticals Inc 's second quarter 2022 Operating Income $ -0.35 millions Quarterly RSPI's Income Statement
New: More RSPI's historic Operating Income Growth >>


RSPI Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Respirerx Pharmaceuticals Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RSPI's II. Quarter Q/Q Operating Income Comment
II. Quarter 2023 results of -0.47 millions by Respirerx Pharmaceuticals Inc appear even worse considering the -0.39 millions in the first quarter.

Within Major Pharmaceutical Preparations industry Respirerx Pharmaceuticals Inc achieved highest sequential Operating Income growth. While Respirerx Pharmaceuticals Inc 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RSPI's II. Quarter Q/Q Operating Income Comment
Current accomplishment of -0.47 millions by Respirerx Pharmaceuticals Inc come out even worse if you take a look at -0.39 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Respirerx Pharmaceuticals Inc achieved highest sequential Operating Income growth. While Respirerx Pharmaceuticals Inc 's Operating Income growth quarter on quarter, overall rank is .


Respirerx Pharmaceuticals Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
Cumulative Operating Income 12 Months Ending $ -1.47 $ -1.35 $ -1.58 $ -1.87 $ -2.06
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment


Respirerx Pharmaceuticals Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment


Respirerx Pharmaceuticals Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
RSPI's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for RSPI's Competitors
Operating Income Growth for Respirerx Pharmaceuticals Inc 's Suppliers
Operating Income Growth for RSPI's Customers

You may also want to know
RSPI's Annual Growth Rates RSPI's Profitability Ratios RSPI's Asset Turnover Ratio RSPI's Dividend Growth
RSPI's Roe RSPI's Valuation Ratios RSPI's Financial Strength Ratios RSPI's Dividend Payout Ratio
RSPI's Roa RSPI's Inventory Turnover Ratio RSPI's Growth Rates RSPI's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Jun 30 2023
Elite Pharmaceuticals Inc 56.65%$ 56.649 millions
United Therapeutics Corporation55.30%$ 55.302 millions
Cardiff Lexington Corporation54.73%$ 54.729 millions
Msa Safety Incorporated54.39%$ 54.394 millions
Biomarin Pharmaceutical Inc50.36%$ 50.363 millions
Amphastar Pharmaceuticals Inc 48.64%$ 48.636 millions
Conduit Pharmaceuticals Inc 45.40%$ 45.396 millions
Harmony Biosciences Holdings inc 41.63%$ 41.629 millions
Ufp Technologies Inc 39.70%$ 39.700 millions
Option Care Health Inc 39.43%$ 39.425 millions
Harrow Inc 39.17%$ 39.172 millions
Semler Scientific Inc 38.66%$ 38.664 millions
Abbvie inc 36.97%$ 36.965 millions
Pro dex Inc 36.21%$ 36.210 millions
Airsculpt Technologies Inc 35.30%$ 35.302 millions
Neurocrine Biosciences Inc 34.55%$ 34.552 millions
Select Medical Holdings Corp31.61%$ 31.609 millions
Medpace Holdings Inc 30.14%$ 30.143 millions
Pacira Biosciences inc 27.67%$ 27.668 millions
Surgery Partners Inc 27.58%$ 27.582 millions
Addus Homecare Corporation27.49%$ 27.495 millions
Stryker Corp25.00%$ 25.000 millions
Radnet Inc 24.97%$ 24.967 millions
Merit Medical Systems Inc23.89%$ 23.891 millions
Amgen Inc 23.35%$ 23.346 millions
Sonida Senior Living Inc 22.41%$ 22.409 millions
Nature s Sunshine Products inc 22.28%$ 22.276 millions
Vaso Corporation22.15%$ 22.151 millions
Boston Scientific Corporation21.51%$ 21.513 millions
Gt Biopharma Inc 20.14%$ 20.139 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com